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activities constructed in the previous steps. Results indi-
cated that in step 1, after alterations and exclusions, 28/70 
activities could be retained. Nine newly generated activi-
ties were subsequently added in step 2. In step 3, the 37 
activities were presented to the patient-proxy dyads. Based 
on their input, several additional alterations and exclusions 
were made resulting in a list of 32 activities. In conclusion, 
this evaluation of the A-IADL-Q showed that dementia-
specific IADL activities are only partly applicable to gli-
oma patients, and that the addition of glioma specific IADL 
activities is necessary to capture the IADL construct. This 
underlines the need for a disease-specific IADL question-
naire for brain tumor patients.
Keywords IADL · Activities of daily living · Glioma · 
Brain tumor · Daily functioning · Amsterdam IADL 
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Introduction
Traditional outcome measures used in clinical trials with 
brain tumor patients are overall and progression-free sur-
vival and tumor response on magnetic resonance imaging. 
In addition, information on patients’ functioning and well-
being has become increasingly important, especially in 
patients with an incurable disease. The quality of survival 
in brain tumor patients is arguably at least as important as 
the duration of survival [1].
One way to measure patients’ functioning is with activi-
ties of daily living (ADL). ADL can be divided into two 
categories, basic activities of daily living (BADL) and 
instrumental activities of daily living (IADL). BADL are 
basic skills needed for self-maintenance such as feeding, 
bathing, dressing, and toileting [2]. IADL on the other 
Abstract Both dementia and brain tumor patients exhibit 
cognitive decline during the course of their disease. They 
might therefore experience similar problems with cogni-
tively complex daily activities (i.e., instrumental activities 
of daily living (IADL)). The study’s objective is to evalu-
ate if the Amsterdam IADL  Questionnaire© (A-IADL-Q), 
a 70-item IADL questionnaire developed for and validated 
in early dementia patients, is also applicable to glioma 
patients. The evaluation consisted of three steps. Predeter-
mined decision rules defined which activities were retained, 
altered, added or excluded. In the first step, 6 neuro-oncol-
ogy health care professionals (HCP) and 10 glioma patient-
proxy dyads were asked to evaluate the 70 A-IADL-Q 
activities. In the second step, in-depth interviews were 
conducted with 6 HCPs and 6 other patient-proxy dyads to 
generate relevant activities specific to glioma patients not 
covered by the A-IADL-Q. In the third step, 6 new patient-
proxy dyads were cognitively debriefed with the list of 
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hand, includes more cognitively complex activities such as 
food preparation, handling finances, shopping, housekeep-
ing or using electronics (i.e., a telephone or computer) [3]. 
These capacities are essential to function autonomously 
within society. IADL functions seem to be sensitive to 
the early effects of cognitive decline [4]. Since cognitive 
decline is characteristic of brain tumor patients, measuring 
IADL is especially relevant.
Commonly used ADL scales and questionnaires in brain 
tumor patients such as the Barthel Index [5] and the Kar-
nofsky performance status [6], only cover BADL. Even 
though the functional independence measure (FIM) [7], 
whether or not in combination with the functional assess-
ment measure (FAM) [8], assesses problems in activities of 
daily living, it also includes cognitive abilities, such as con-
centration and memory, and emotional status. These items 
cover different constructs. Moreover, these questionnaires 
have several other limitations. First of all, most of these 
questionnaires were developed in the late 1950s, with more 
recent revisions in the early 1990s. Advances in technol-
ogy have changed our daily environment dramatically (e.g., 
the use of mobile phones, computers and household appli-
ances) [9]. Secondly, the quality demands on self-report 
questionnaires have increased in the meantime. Although 
most psychometric properties of these questionnaires have 
been shown to be adequate [10, 11], there are still some 
limitations. For example, the FIM-FAM has not been vali-
dated in brain tumor patients.
Although there is no gold standard to measure IADL 
specifically in brain tumor patients, a recently proxy-
based questionnaire was developed and validated to meas-
ure IADL problems in patients with early dementia [12]. 
Since cognitive deficits are present in both early dementia 
patients and brain tumor patients during the course of the 
disease, regardless of whether this is a result of the disease 
or its treatment, we expected they might exhibit similar 
IADL problems.
Therefore, the objective of this pilot study was to evalu-
ate if the Amsterdam IADL  Questionnaire© (A-IADL-Q) is 
also applicable to glioma patients.
Methods
Participants
Adult patients (1) with a histologically confirmed diffuse 
glioma (World Health Organisation (WHO) grade II dif-
fuse astrocytoma, oligodendroglioma or oligoastrocytoma, 
WHO grade III anaplastic astrocytoma, anaplastic oligo-
dendroglioma or anaplastic oligoastrocytoma or WHO 
grade IV glioblastoma), (2) who are in frequent contact 
(daily or weekly) with their proxies and (3) native Dutch, 
were eligible and recruited from the neuro-oncology out-
patient clinics of the VU University Medical Center in 
Amsterdam and the Medical Center Haaglanden in The 
Hague, the Netherlands. Before each outpatient clinic, all 
attending patients were screened for eligibility and those 
eligible were invited to participate. With this method, we 
hoped to ensure a representative sample of the diffuse gli-
oma population. Furthermore, two neuro-oncologists, two 
specialised neuro-oncology research nurses and two neu-
ropsychologists were included as health care professionals 
(HCPs). The study was approved by the Medical Ethical 
Committee of the VU University Medical Center, Amster-
dam, The Netherlands.
Materials
The Amsterdam IADL  Questionnaire© (A-IADL-Q) is 
an informant-based questionnaire [4]. The A-IADL-Q 
has been shown to have favourable psychometric proper-
ties, high internal consistency and test–retest reliability, 
and good content and construct validity in memory clinic 
patients [4, 12]. The A-IADL-Q consists of 70 items and 
is computerized and adaptive, and scores are calculated 
using item response theory (IRT; statistical framework 
that describes the relationship between a patient’s response 
to an item and his/her level of the underlying construct, 
e.g., IADL, that is being measured). For each activity, the 
‘main’ item would be whether or not the person had done 
the activity in the past 4 weeks, and the ‘follow-up’ item 
would be either; whether or not they had experienced more 
difficulties with the activity or for what reason they were 
unable to do the activity (due to physical issues, men-
tal issues, never partaken in the activity or other). The 
A-IADL-Q was found to be relevant and important by both 
patients and proxies, the respondent burden to be limited, 
and the method of data collection (on a tablet) to be user-
friendly [12].
Procedure
Using a multi-step approach, the applicability of the 
A-IADL-Q for glioma patients was evaluated [4, 13].
Step 1: Evaluation of the activities in the Amsterdam IADL 
 Questionnaire©
Six HCPs as well as ten patients with a glioma and their 
proxies (total n = 2 × 10 = 20) were requested to evaluate 
the main A-IADL-Q activities. HCPs evaluated the activi-
ties on three aspects; (I) can the activity be considered 
IADL using the proposed definition (=‘IADL are complex 
activities with little automated skills for which multiple 
cognitive processes are necessary’ [4]), (II) is the activity 
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likely to be affected in glioma patients, and (III) is the item 
clearly defined and formulated? The inclusion criteria were 
as follows; ≥5/6 HCPs had to affirm that the activity was 
IADL, ≥4/6 HCPs had to recognize the activity as likely to 
be affected and ≥5/6 HCPs had to consider the item to be 
clearly formulated to be considered clear.
Patients and their proxies only needed to consider two 
questions; (I) is the activity likely to be affected in glioma 
patients, and (II) is the item clearly defined and formu-
lated? At least 3/10 patients/proxies had to recognize the 
activity as likely to be affected and ≥9/10 patients/proxies 
had to consider the item to be clearly formulated to be con-
sidered clear.
Step 2: Generating relevant IADL activities not covered 
by the Amsterdam IADL  Questionnaire©
The same HCPs (n = 6) and another group of patients and 
their proxies (total n = 2 × 6 = 12) were interviewed to 
assess which IADL are affected in glioma patients, but not 
covered by the existing activities in the A-IADL-Q. To do 
so, in-depth semi-structured interviews with open questions 
were conducted using the ‘sampling-to-redundancy’ crite-
rion [14]. Only the activities that were in accordance with 
the proposed IADL definition and mentioned by ≥3 HCPs 
or patients and proxies were included.
The A-IADL-Q activities retained after step 1 were 
activities that were considered either (a) IADL, affected 
and clearly defined or (b) IADL and affected, but not 
clearly defined. In the latter case, the items were rephrased. 
In addition, if step 2 revealed that certain relevant activities 
were not covered by the A-IADL-Q, an item on this activ-
ity was formulated. These two steps resulted in a new set 
of activities that was believed to measure IADL in glioma 
patients, and was cognitively debriefed in step 3.
Step 3: Cognitive debriefing of the new list of activities
A new group of 6 glioma patients and their proxies (total 
n = 2 × 6 = 12) underwent a cognitive debriefing. This tech-
nique was used to test whether all activities were inter-
preted as intended. If ≥2 participants indicated similar 
mentions of ambiguity or repetitiveness, we rephrased, 
merged or omitted the item.
Statistics
Descriptive statistics were used to analyse the clinical and 
demographic variables of the study population and the 
responses of the participants. Statistical analyses were per-
formed using SPSS version 21.0 software (SPSS, Chicago, 
IL, USA).
Results
A total of 50 participants were included in this study; 22 
patients, 22 proxies and 6 HCPs (Table 1). Ten low-grade 
and 12 high-grade glioma patients were included. More 
than half of the patients were male. All proxies were the 
patient’s partner. Most proxies have been in a relationship 
with the patient for  over 10  years. The six experienced 
HCPs consisted of 2 neuro-oncologists, 2 specialised 
neuro-oncology research nurses and 2 neuropsychologists.
Step 1: Evaluation of the activities in the Amsterdam 
IADL  Questionnaire©
Question I: Can the activity be considered IADL?
Six HCPs evaluated if the 70 activities in the A-IADL-Q 
could be considered as IADL. Almost all items were con-
sidered to be IADL (67/70; 96%). The disagreement in 
these three cases can be explained by the format in which 
the items were presented (adaptive vs. non-adaptive). 
Although the activities were considered as IADL, the 70 
main items in the A-IADL-Q were not formulated in a way 
that they could be considered IADL, while the follow-up 
item was. The A-IADL-Q follow-up items were in line with 
the suggestions made by our HCPs.
Question II: Affected in glioma patients?
Ten patients, ten proxies and six HCPs evaluated if the 
70 activities in the A-IADL-Q were affected in glioma 
patients. HCPs considered 44/70 (63%) of the activities as 
likely to be affected in glioma patients. Patients and proxies 
recognized only 14/70 (20%) and 15/70 (21%) of the activi-
ties as affected, respectively. Concordance between patients 
and proxies was 97%.
Question III: Clearly defined and formulated?
Participants evaluated if the 70 items in the A-IADL-Q 
were clearly defined and formulated. HCPs rated only half 
(36/70, 51%) of the items as clearly defined and formulated. 
On the other hand, patients and proxies rated 65/70 (93%) 
and 60/70 (82%) items as clear, respectively. Thirty-three 
out of 70 (47%) items were considered clearly formulated 
by all participants.
Based on the input of all participants, 48/70 (69%) 
activities were considered likely to be affected in glioma 
patients by either the patients, proxies or HCPs, with 
22/48 items being considered both affected and clear 
(Fig.  1). Of the 26/48 unclear items, seven items were 
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rephrased, four items were merged and 11 items were 
integrated in other items. In some cases (n = 7), items 
were considered to be clear, but HCPs suggested the 
items should be omitted because they were considered 
repetitive (n = 6) or redundant (n = 1). Step 1 resulted in a 
list of 28 items being considered both IADL, affected and 
clearly formulated.
Step 2: Generating relevant IADL activities not covered 
by the Amsterdam IADL  Questionnaire©
The results of the in-depth interviews revealed several 
IADL which are affected in glioma patients, but not cov-
ered by the A-IADL-Q (Table 2). During the interviews, 
both HCPs and the patients and proxies mentioned ‘mul-
titasking’ and ‘keeping appointments’ as missing. Moreo-
ver, HCPs mentioned numerous other activities affected 
in glioma patients, such as ‘organizing activities’. The 
activity uniquely mentioned by the patients and their 
proxies was, ‘having a conversation with several people 
at the same time’. Nine new activities were formulated.
Step 3: Cognitive debriefing of the new list of activities
The 28 activities resulting from step 1 and the nine 
newly formulated activities in step 2 were merged 
(Fig. 1), resulting in a provisional item list of 37 activi-
ties (Appendix 1), which was cognitively debriefed by 
six new patient-proxy dyads. Based on their input sev-
eral additional alterations and exclusions were made 
(Fig.  1), resulting in a final item list consisting of 32 
activities (Appendix 2).
Discussion
Based on the similarities in cognitive decline between 
patients with early dementia and a glioma, we hypoth-
esized that the A-IADL-Q, developed for and validated in 
dementia patients, could possibly be applicable for glioma 
patients. Surprisingly, results showed that, even though 
eventually all activities of the A-IADL-Q were considered 
IADL, only a number of the activities were considered 
Table 1  Participants’ clinical 
and demographic characteristics
a Level of education according to international standard classification of education ranging from 0 (low) to 
8 (high) [15]
Participants Patients (N = 22) Proxies (N = 22) HCPs (N = 6)
Gender (male), n (%) 12 (55%) 10 (45%) 2 (33%)
Age, mean (SD) 52 (13) 53 (14) 47 (12)
Median (range) 50 (25–76) 51 (27–75) 47 (−64)
Level of educationa, n (%)
0–4 13 (59%) 13 (59%)
5–8 9 (41%) 9 (41%)
Relation to the patient, n (%)
Partner 22 (100%)
Contact intensity, n (%)
Living together 22 (100%)
Duration of the relationship (in 
years), mean (SD)
23 (11.87)
<5 years 0 (0%)
5–10 years 6 (27%)
>10 years 16 (73%)
Histological diagnosis, n (%)
WHO grade II 10 (46%)
WHO grade III 6 (27%)
WHO grade IV 6 (27%)
Disease status, n (%)
Stable 19 (86%)
Progressive 3 (14%)
Anti-tumor treatment status, n (%)
Current anti-tumor treatment 4 (18%)
No current anti-tumor treatment 18 (82%)
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applicable to glioma patients. Furthermore, several rel-
evant IADL to glioma patients were not covered by the 
questionnaire.
A striking but explicable result was the discrepancy 
between the HCPs and the patients and proxies. HCPs 
considered about three times as many activities affected in 
Fig. 1  Flowchart reflecting the steps taken to assess the applicability of the Amsterdam IADL  Questionnaire© for glioma patients
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glioma patients compared to patients and proxies. Indeed, 
patients and proxies only have their own situation as refer-
ence, whereas HCPs have broader knowledge of and expe-
rience with potential problems glioma patients might face. 
On the other hand, patients and proxies considered almost 
twice as many items as well-defined compared to HCPs. 
This also is understandable considering the HCPs have a 
more critical approach to evaluating items than patients and 
proxies. For instance, HCPs evaluated the wording more 
closely to ensure it is appropriate for people with differ-
ent levels of education and background. However, in most 
cases the HCPs in this study seemed to rate the items as 
unclearly defined because of the redundancy and repetitive-
ness of the items. This is most likely due to the fact that the 
A-IADL-Q is scored using IRT and in this study all main 
items were presented.
The A-IADL-Q might not be as applicable to glioma 
patients for several reasons. First of all, factors such as age 
might account for the discrepancies. Although the risk of 
a glioma increases with age, many relatively young indi-
viduals are diagnosed with this disease when compared 
to dementia. Our study population was about 10 years 
younger than the study population used in the development 
of the A-IADL-Q. Especially the types of activities gen-
erated in step 2 (activities focus mainly on socially active 
and occupationally related subjects) seem to point to a dif-
ference in generation or stage of life. Another factor might 
be a difference in disease severity. Early dementia patients 
group might already be more severely cognitive impaired 
when seeking medical assistance. Moreover, other cogni-
tive domains might be affected in glioma patients. The 
most prominent impairment in patients with dementia is 
memory loss [16]. Glioma patients can exhibit a range of 
neurocognitive deficits in areas such as language, mem-
ory, executive functioning, attention and motor function 
[17–19]. Tucha and colleagues documented the incidence 
of cognitive impairments immediately after diagnosis but 
before the start of treatment among patients with frontal 
or temporal brain tumors and found that ±90% of patients 
demonstrated impairments in at least one aspect of cogni-
tion and one-third of the patients demonstrated impaired 
functioning in eight or more cognitive areas [18]. The most 
commonly identified impairment in the study was in execu-
tive functioning. A number of studies have shown a strong 
association between executive functioning and having dif-
ficulties with appropriately initiating and completing IADL 
[3]. This suggests that the discrepancies between dementia 
patients and brain tumor patients might be due to differ-
ences in the predominant underlying cognitive impairment 
and the number of impaired cognitive domains. Moreover, 
cognitive problems in glioma patients might also be more 
diversified due to differences in tumor characteristics (e.g., 
volume and location) within the patient group. Another 
aspect might be that brain tumor patients could also have 
problems with IADL due to physical problems (for instance 
loss of motor function or sensory problems), epilepsy or 
non-tumor related issues such as advanced age, comorbid-
ity and legal issues (e.g., not allowed to drive a car because 
of epilepsy) [20, 21].
Evidently, this study has some limitations. First of all, 
the sample size was relatively small. Therefore, the prob-
lems the patients indicated may not completely reflect 
those of the ‘whole’ glioma population. Secondly, a selec-
tion bias could have been introduced by including the more 
healthy patients in this study [22]; patients with, for exam-
ple, severe cognitive impairments, psychological distress 
or declined physical conditions often not participate [20]. 
Indeed, the majority of the patients in this study had sta-
ble disease. We have tried to overcome this by also consult-
ing HCPs selected from different disciplines (physicians, 
psychologist and nurses), who encounter patients from all 
stages of the disease. Furthermore, the generalizability of 
this study is limited because only Dutch natives and only 
glioma patients were included. Patients with other types of 
primary brain tumors or those with brain metastases were 
not included. Finally, the newly generated activities have 
not been validated as IADL by HCPs.
Future perspective
The results of this pilot study clearly suggest the necessity 
of a disease-specific IADL questionnaire for brain tumor 
patients. Currently, the development of an IADL question-
naire for brain tumor patients is in progress, in accord-
ance with the EORTC Quality of Life Group guidelines 
for developing questionnaire modules [13]. The study will 
include a larger patient population, with both patients with 
a primary brain tumor and patients with brain metastases, 
Table 2  Novel instrumental activities of daily living generated by 
≥ 3 HCPs (n = 6) and ≥ 3 patient-proxy dyads (n = 6) during the in-
depth interviews
Newly generated activities HCPs n = 6 Patients and 
proxies n = 6
Organizing/initiating social activities 6 (100%) –
Reading a book or newspaper 6 (100%) –
Multitasking 5 (83%) 4 (67%)
Finishing work on time 5 (83%) –
Following a TV programme or movie 5 (83%) –
Keeping appointments 4 (67%) 4 (67%)
Having a conversation with several 
people at the same time
– 4 (67%)
Learning new things 3 (50%) –
Overseeing one’s own activities 3 (50%) –
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and the questionnaire will be cross-culturally validated. 
The list of 32 activities derived from this pilot study will 
be used in the developmental process of the questionnaire.
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Appendix 1: IADL item list after step 1 and 2
During the past month, did you have difficulty with…
Household duties:
(1) Grocery shopping independently?
(2) Buying the correct groceries?
(3) Preparing sandwich meals?
(4) Preparing/cooking hot meals?
(5) Using domestic appliances (like the microwave, oven, 
dishwasher, coffee maker or washing machine)?
(6) Doing chores or minor repairs in or around the house?
Finances and administration:
(7) Doing the financial administration?
(8) Using electronic banking?
(9) Withdrawing money at an ATM or paying with a card 
in a store?
(10) Paying cash?
(11) Filling in forms?
Appliances:
(12) Using a mobile telephone or smartphone?
(13) Understanding an instruction manual?
(14) Operating the television remote control?
Work:
(15) Functioning adequately (as previously) at work?
(16) Finishing your work on time?
Appointments:
(17) Making appointments independently?
(18) Keeping your appointments?
(19) Planning or organizing an activity?
Computer:
(20) Using a computer?
(21) Searching the Internet for information?
(22) Using email?
Social activities:
(23) Having a conversation with several people?
Transport:
(24) Driving a car?
(25) Driving a car safely?
(26) Operating a car navigation system?
(27) Using public transport independently?
(28) Finding your way in an unfamiliar surrounding?
Leisure time:
(29) Following programs on television?
(30) Reading a book, magazine or newspaper?
(31) Going on holiday or a day out?
General:
(32) Finding important items (such as wallet, keys or 
phone) around the house?
(33) Dealing with unexpected circumstances?
(34) Overseeing your activities?
(35) Doing several things at once (multitasking)?
(36) Being able to take your medication independently?
(37) Learning to do new things?
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Appendix 2: IADL item list after step 3
During the past month, did you have difficulty with…  
Household duties:
(1) Grocery shopping independently?
(2) Preparing a meal?
(3) Using household appliances (such as the telephone, 
microwave, oven, dishwasher, coffee maker or wash-
ing machine)?
(4) Doing chores or minor repairs in or around the house?
Finances and administration:
(5) Keeping the financial administration in order?
(6) Using electronic banking?
(7) Withdrawing money at an ATM or paying with a card 
in a store?
(8) Paying cash?
(9) Filling in (digital) forms?
Appliances:
(10) Using a mobile telephone or smartphone?
(11) Following an instruction manual?
(12) Using a (television) remote control?
(13) Using a computer (like browsing, emailing or using 
computer programs)?
Work:
(14) Functioning normally (as previously) at work?
(15) Finishing your work on time?
Appointments:
(16) Making appointments independently?
(17) Keeping appointments?
(18) Planning or organizing an activity (such as a birthday, 
dinner or a night out)?
Social activities:
(19) Having a one-on-one conversation?
(20) Having a group discussion?
Transport:
(21) Driving a car safely?
(22) Using a navigation system?
(23) Using public transport independently?
(24) Finding the way in unfamiliar surrounding?
Leisure time:
(25) Following a television program or movie?
(26) (Comprehensively) reading a book, magazine or news-
paper?
General:
(27) Finding important items (such as wallet, keys or 
phone) around the house?
(28) Changing your activity when an unexpected situation 
arises?
(29) Overseeing your activities?
(30) Doing several things at once (multitasking)?
(31) Managing your own medication independently?
(32) Learning to do new things (such as a course, computer 
program or appliance)?
References
 1. Efficace F, Taphoorn M (2012) Methodological issues in design-
ing and reporting health-related quality of life in cancer clini-
cal trials: the challenge of brain cancer studies. J Neurooncol 
108(2):221–226
 2. Lawton MP, Brody EM (1969) Assessment of older people: self-
maintaining and instrumental activities of daily living. Geron-
tologist 9(3):179–186
 3. Overdorp EJ et al (2016) The combined effect of neuropsycho-
logical and neuropathological deficits on instrumental activities 
of daily living in older adults: a systematic review. Neuropsychol 
Rev 26(1):92–106
 4. Sikkes SA et al (2012) A new informant-based questionnaire for 
instrumental activities of daily living in dementia. Alzheimers 
Dement 8(6):536–543
 5. Mahoney FI, Barthel DW (1965) Functional evaluation: the Bar-
thel Index. Md State Med J 14:61–65
 6. Mackworth N, Fobair P, Prados MD (1992) Quality of life self-
reports from 200 brain tumor patients: comparisons with Karnof-
sky performance scores. J Neurooncol 14(3):243–253
 7. O’Dell MW et al (1998) Functional outcome of inpatient reha-
bilitation in persons with brain tumors. Arch Phys Med Rehabil 
79(12):1530–1534
 8. Hall KM et al (1993) Characteristics and comparisons of func-
tional assessment indices: disability rating scale, functional inde-
pendence measure, and functional assessment measure. J Head 
Trauma Rehabil 8(2):60–74
 9. Rosenberg L et al (2009) Perceived difficulty in everyday tech-
nology use among older adults with or without cognitive deficits. 
Scand J Occup Ther 16(4):216–226
 10. Hobart JC et  al (2001) Evidence-based measurement: which 
disability scale for neurologic rehabilitation? Neurology 
57(4):639–644
 11. Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky perfor-
mance status revisited: reliability, validity, and guidelines. J Clin 
Oncol 2(3):187–193
 12. Sikkes SA et  al (2013) Validation of the Amsterdam IADL 
Questionnaire(c), a new tool to measure instrumental activities 
of daily living in dementia. Neuroepidemiology 41(1):35–41
153J Neurooncol (2017) 132:145–153 
1 3
 13. Johnson C et al., EORTC Quality of life group (2011) Guidlines 
for Developing Questionnaire Modules
 14. Streiner DL, Norman GR (2008) Health Measurement Scales: 
A practical guide to their development and use. Health measure-
ment scales: a practical guide to their development and use. 2008 
Oxford University Press, Oxford, pp 1–452.
 15. Schneider SL (2011) The International Standard Classification of 
Education 2011, in Class and Stratification Analysis. pp 365–379
 16. Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, 
diagnostic criteria, risk factors and biomarkers. Biochem Phar-
macol 88(4):640–651
 17. Gehrke AK et  al (2013) Neurocognitive deficits following pri-
mary brain tumor treatment: systematic review of a decade of 
comparative studies. J Neurooncol 115(2):135–142
 18. Tucha O et al (2000) Cognitive deficits before treatment among 
patients with brain tumors. Neurosurgery 47(2):324–333 (dis-
cussion 333–334)
 19. Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients 
with brain tumours. Lancet Neurol 3(3):159–168
 20. Sterckx W et  al (2013) The impact of a high-grade glioma on 
everyday life: a systematic review from the patient’s and caregiv-
er’s perspective. Eur J Oncol Nurs 17(1):107–117
 21. Chandana SR et  al (2008) Primary brain tumors in adults. Am 
Fam Physician 77(10):1423–1430
 22. Dirven L et  al (2013) Health-related quality of life in patients 
with brain tumors: limitations and additional outcome measures. 
Curr Neurol Neurosci Rep 13(7):359
